Amova Asset Management Americas Inc. Sells 179,231 Shares of Twist Bioscience Corporation $TWST

Amova Asset Management Americas Inc. reduced its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 7.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,120,206 shares of the company’s stock after selling 179,231 shares during the period. Amova Asset Management Americas Inc.’s holdings in Twist Bioscience were worth $59,641,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 5.1% during the 3rd quarter. ARK Investment Management LLC now owns 6,726,808 shares of the company’s stock valued at $189,292,000 after acquiring an additional 326,367 shares during the last quarter. Artisan Partners Limited Partnership boosted its position in Twist Bioscience by 26.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after purchasing an additional 1,349,867 shares during the period. William Blair Investment Management LLC boosted its position in Twist Bioscience by 6.0% during the third quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock worth $116,564,000 after purchasing an additional 235,679 shares during the period. EdgePoint Investment Group Inc. grew its holdings in Twist Bioscience by 114.3% during the second quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company’s stock valued at $87,779,000 after purchasing an additional 1,272,732 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in shares of Twist Bioscience by 14.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock valued at $41,171,000 after purchasing an additional 184,726 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TWST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Robert W. Baird set a $50.00 price target on Twist Bioscience in a research report on Tuesday, February 3rd. Barclays lifted their price objective on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Evercore raised their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.88.

Twist Bioscience Trading Up 3.0%

Shares of TWST opened at $48.06 on Thursday. The stock’s 50-day moving average price is $43.03 and its 200 day moving average price is $34.31. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $57.88. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -37.55 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. The business’s revenue was up 16.9% compared to the same quarter last year. As a group, research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Jan Johannessen sold 2,200 shares of Twist Bioscience stock in a transaction on Friday, February 6th. The stock was sold at an average price of $47.91, for a total transaction of $105,402.00. Following the completion of the transaction, the director directly owned 17,754 shares of the company’s stock, valued at approximately $850,594.14. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dennis Cho sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00. Following the completion of the sale, the insider directly owned 138,581 shares in the company, valued at approximately $6,919,349.33. The trade was a 3.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 36,609 shares of company stock worth $1,665,151 in the last 90 days. 3.08% of the stock is currently owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.